Corporate Strategy

A projected $127 billion shortfall in aviation carbon credits is not an abstract compliance problem. It is a cost that sits between airlines and their current ticket pricing, and the pressure will transmit to fares at a time when carriers are already managing fuel and labour inflation. The mechanism is CORSIA, the international offset scheme that requires airlines to purchase credits for emissions above 2019 baseline levels, and the supply of eligible credits is structurally insufficient relative to the volume of flying now projected through the early 2030s. IAG, which operates British Airways and Iberia, is among the carriers most exposed given its long-haul mix. Investors in airline equity should treat this as a margin headwind that is not yet priced into most forward earnings models, and UK leisure operators with contracted seat blocks should be modelling the pass-through risk now.

Survey data showing one in three UK businesses prioritising business rates reform above other fiscal asks is a useful political temperature check. The current regime taxes physical premises on a valuation methodology that was last fundamentally reformed in 1988, which means it systematically penalises retailers, hospitality operators, and light manufacturers relative to digital-first competitors with minimal floor space. The practical stakes: business rates currently raise around £26 billion a year for local authorities, and any meaningful cut requires either a replacement revenue source or a direct hit to council funding. Labour's 2024 manifesto promised reform but not abolition. With a spending review looming and growth numbers disappointing, the Chancellor faces the standard tradeoff: cut rates and lose revenue, hold rates and lose business investment. Operators with significant property footprints should be engaging with their industry bodies now to shape the consultation rather than react to it.

Already covered in Markets and Economy.

Germany's Merck KGaA is buying US biotech tools company Bio-Techne for $11.3 billion, a deal that cements its position in the high-margin life science reagents and instruments market rather than pursuing the riskier drug-development path. Bio-Techne supplies proteins, antibodies, and assay kits to pharmaceutical researchers globally, giving Merck a recurring-revenue infrastructure play inside every major drug pipeline. At a time when Big Pharma is under US pricing pressure via the Inflation Reduction Act's Medicare negotiation provisions, selling picks and shovels to the industry looks considerably more defensible than owning the drugs themselves. London-listed life science tools peers, including Oxford Instruments and Spectris, will be repriced on deal comps by close of play today.

Jamie Dimon has upended JPMorgan's succession race for at least the second time in two years, with internal candidates repositioned and timelines left deliberately unclear. This is a well-worn pattern: Dimon periodically resets the hierarchy in a way that keeps rivals off-balance and reinforces his own indispensability to the board. The strategic cost is real. JPMorgan's closest competitors, including Goldman Sachs under David Solomon and Morgan Stanley under Ted Pick, have cleaner succession pictures, which matters to institutional clients assessing long-term relationship risk. BHP, separately, is also reshuffling leadership ahead of incoming CEO Simon Fletcher-Craig's official start, splitting the Americas role in a restructuring that signals he intends to impose his own management layer before day one.

Law firms are discovering that AI's first major contribution to their sector is generating litigation, not reducing it. Ethical AI disputes are opening a wave of new cases as clients challenge model outputs, training data provenance, and liability for automated advice, creating a new practice area faster than any efficiency gain can offset it. Wall Street firms are simultaneously grappling with fresh insider trading exposure as AI tools capable of pattern-recognition across non-public data channels sit inside the same institutions managing material information. In-house legal teams see the productivity argument clearly but are moving slowly, because the reputational and regulatory downside of an AI-driven compliance failure at a major financial institution outweighs the billing efficiency on the upside. The practical implication for legal tech founders: enterprise sales cycles are long not because GCs are sceptical of the technology, but because they are correctly terrified of being first.

AI adoption inside large organisations remains far below the rate that the volume of enterprise AI announcements would suggest, and the friction is structural rather than technical. The barrier is not model capability; it is that deploying AI at scale inside a regulated business requires clean data, clear accountability lines, and an answer to the question of who is liable when it goes wrong. Most large UK enterprises have none of these three things in adequate shape. The companies that have crossed the adoption threshold share one characteristic: a senior executive who owns the outcome personally and has tied their career to the deployment rather than delegating it to IT. If your organisation's AI programme reports to a committee, it is not a programme, it is a hedge.

Darden Restaurants, which owns Olive Garden and LongHorn Steakhouse, reported higher overall sales but guided for slower growth and posted disappointing Olive Garden same-store figures, a combination that reflects the specific pressure on mid-price casual dining as lower-income US consumers pull back. Olive Garden is not a luxury brand or a fast-food value play: it sits precisely in the segment most exposed when real wages are being eroded by the inflation data reported this morning. For UK hospitality operators watching the US as a leading indicator, the Darden numbers are a warning that even established, well-run chains cannot insulate themselves from a squeezed middle-income consumer. The July VAT adjustment for UK hospitality provides some relief domestically, but the demand backdrop is the variable that matters more.

Noel Tata, who took the Tata Group chair following Ratan Tata's death, is speaking publicly about the conglomerate's fashion expansion, one of the less-noticed diversifications inside a group better known for steel, cars, and IT. Worth watching as an indicator of where India's largest private conglomerate sees domestic consumption heading.

Oracle has done something most tech executives quietly avoid: it has named the cause. Twenty-one thousand jobs gone in a year, and the company is attributing the cuts directly to AI automation rather than burying them in restructuring language. That specificity matters. It gives every CFO in enterprise software a reference point, and every workforce planner a number to model against. The second-order effect is the harder one: Oracle is not a startup running lean. It is a 47-year-old infrastructure giant with 150,000-plus employees, and if automation is moving at this pace there, the companies telling staff that AI will only affect 'low-skill tasks' have a credibility problem they cannot sustain much longer. The timing, landing against a broader tech sell-off hitting Asian markets overnight, lands poorly for anyone still arguing the employment disruption is theoretical.

Meta selling smart glasses under its own brand rather than through the Ray-Ban partnership is a direct signal that it now believes the product has enough consumer recognition to stand without Luxottica's halo. The price cut sharpens the competitive logic: this is a volume play, not a premium one, aimed at making the glasses a viable platform for AI assistants rather than a fashion accessory. The strategic bet is that first-party hardware at accessible price points builds the data layer Meta needs for ambient AI. The risk is that without Ray-Ban's brand, Meta is asking consumers to accept Meta-branded hardware on their faces, which is a different proposition entirely given the company's trust deficit in European markets. The FCA and ICO will both be watching what data the glasses collect and how it is disclosed.

The Issa brothers taking EG Group to the US rather than London is a pointed verdict on the LSE's appeal for founder-led, leveraged operators with complicated balance sheets. EG Group carries significant debt from a decade of acquisitions, and US markets have historically been more tolerant of leverage when it is attached to a growth narrative and a petrol-forecourt-to-convenience-store transformation story. The $1 billion target is aggressive given current credit conditions, but the US listing route gives the Issas access to a deeper pool of high-yield-adjacent equity investors. For the UK listings debate, the optics are not helpful: this is a Blackburn-founded business choosing New York.

A target company's shares rising on a rejected bid usually means the market thinks a higher offer is coming, not that the board made the right call. Edgewell, which owns Schick and Wilkinson Sword, has been trading at a discount to Gillette-owner P&G for years on weaker brand investment and slower e-commerce execution. Whoever made the approach clearly saw the same gap. The board rejection either reflects a valuation disagreement of a few turns of EBITDA, or a genuine belief that the business is worth running independently, and the market is backing the former. Watch for a revised offer or a competing bid; the sector has seen enough consolidation logic in personal care to assume this does not end at the first no.

Kunal Shah founding CRED, which turned credit card bill payments into a premium loyalty platform for India's affluent, is a specific preparation for running WhatsApp in a market where payments, commerce, and social messaging are converging faster than anywhere else. Meta putting him in charge signals that WhatsApp's monetisation ambitions in India, already the app's largest market by users, are shifting from advertising adjacency toward embedded financial services. The constraint is regulatory: the Reserve Bank of India has repeatedly slowed WhatsApp Pay's rollout, limiting it to 100 million users for years despite the platform having 500 million-plus Indian users. Shah's domestic political capital and RBI familiarity is probably as valuable to Meta as his product instincts.

EasyJet's board has rejected a third takeover approach from US private credit firm Castlelake, valuing the airline at approximately £4.7 billion, describing the offer as 'highly opportunistic'. Castlelake is now going over the board's head, urging shareholders directly to back the deal. At £4.7bn, Castlelake is essentially arguing that easyJet's listed valuation is structurally impaired by short-term cycle noise and that the private market can extract more value through a take-private than public markets will allow. EasyJet's board clearly disagrees, but the fact that Castlelake is persisting to a third bid suggests they have run the numbers on shareholder frustration and think the register is receptive. Watch the institutional shareholder response over the next two weeks: if major holders break from the board, this gets interesting fast.

Japan's corporate governance story is at risk of a policy-induced detour. The Tokyo Stock Exchange has spent two years pushing companies trading below book value to improve capital efficiency through buybacks, ROIC targets, and cross-shareholding reductions. The government's new messaging explicitly prioritises growth investment over those shareholder-value metrics, and the tension is real. Japan's average ROE sits at around 9%, roughly half the US rate, and Goldman Sachs describes the market as now entering a 'critical delivery phase' requiring concrete evidence of better returns. The risk is that boards interpret the growth-investment signal as political cover to deploy cash into low-return domestic projects, exactly the behaviour that kept Japanese equities undervalued for two decades. The distinction that matters for foreign investors is whether individual companies have genuine growth pipelines or are simply being nudged to spend. Separating those two groups is where the alpha sits in Japanese equities right now.

Reformation's confidential IPO filing, expected as soon as next week with a potential listing in July, is as much a Permira story as a brand story. The London-based PE firm acquired a majority stake in 2019 and has overseen a revenue doubling to over $300 million; newer reporting from people familiar with the business puts this year's revenue above $500 million, which would make it a material growth story by any DTC fashion standard. CEO Hali Borenstein has stated the company is profitable, with more than 90% of revenue through owned channels (stores and e-commerce) and around 20% from international markets including the UK. The Bloomberg IPO coverage frames Reformation as a test case for whether sustainability-branded fashion can command a public market premium. The honest risk is that recent consumer IPOs have underperformed post-listing when the celebrity halo fades and investors focus on unit economics. Permira's track record includes the Dr. Martens IPO, which listed at roughly £5 billion and subsequently lost most of that value. Goldman Sachs, presumably advising, will be aware.

SpaceX opened on Nasdaq at $150 per share, roughly 11% above its IPO price, and closed day one near $161, generating approximately $75 billion in proceeds and pushing Musk's net worth past the trillion-dollar mark across SpaceX, Tesla, and other holdings. The roll-up framing now circulating on Wall Street is not just rhetorical: Musk has already deployed capital into a reported $60 billion acquisition of AI coding tool Cursor, with SpaceX's stated plans to build satellite-connected in-orbit data centres creating a vertical logic that links space infrastructure to AI compute. SpaceX is currently loss-making, and the investment case is explicitly a long-duration bet on execution rather than current earnings. The more structural concern for competitors is that Musk now holds public-market equity at scale as acquisition currency, a position no other AI or aerospace founder currently occupies. UK institutional investors with mandates to access US tech growth should expect this to be a heavy index inclusion conversation within weeks.

Volkswagen's decision to run a sealed-bid process for its engines business, reported at a $10 billion price target, is an admission that EQT had assembled enough shareholder support to make an open auction structurally unfair. Lone Star has emerged as frontrunner for the Continental industrial unit in a parallel process, suggesting that financial sponsors are the dominant buyers of large European industrial carve-outs right now, with industrial acquirers largely absent. The underlying asset, which covers shipping engines and heat pumps rather than purely automotive powertrains, is a more resilient business than a pure-ICE play, which explains the interest. The broader strategic question for European carmakers is whether asset sales generate enough capital to fund the electrification transition or simply slow the bleeding. Analysts are already arguing that a defence-sector pivot, widely floated as a diversification story for OEMs, will not move the needle at the scale these companies need. Proceeds from the VW and Continental sales will be a cleaner indicator of genuine restructuring intent than any adjacency announcement.

The emerging read on Musk's corporate strategy is not the personality spectacle but the financial architecture: using Tesla's balance sheet, xAI's compute narrative, and X's data assets as interlinked collateral in a roll-up that resembles the 1990s conglomerate playbook more than a conventional tech company. The DOJ's intervention on xAI's gas turbines as a national security matter adds a new variable to that structure, because it means Musk's energy infrastructure strategy, which is central to xAI's ability to train competitive models, is now subject to federal review with national security framing attached. GLP-1 beneficiaries like Glanbia, whose shares have rallied on the thesis that ozempic-era patients shift toward protein supplements rather than away from them, represent an entirely different kind of roll-up logic: consumer behaviour changes creating structural demand for adjacent product categories, with investors willing to pay growth multiples for companies positioned in the right lane of that shift.